Queensland Paediatric Cardiac Service (QPCS), Queensland Children's Hospital, Brisbane, Australia.
School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Australia.
World J Pediatr Congenit Heart Surg. 2023 Mar;14(2):211-219. doi: 10.1177/21501351221149416. Epub 2023 Feb 23.
A systematic review was performed for evaluation of the performance of CardioCel in cardiac surgery. The review included all studies published from January 2013 to December 2020. We conclude that CardioCel is a strong, flexible tissue substitute with good handling characteristics and a low incidence of thrombosis, aneurysm formation, infection, or structural degeneration. It can be used for a variety of intracardiac and extracardiac repairs of congenital heart defects in all age groups with good durability at mid-term follow-up. However, the use of CardioCel in certain positions requires caution. Information on the long-term performance of CardioCel is lacking.
一项系统评价评估了 CardioCel 在心脏手术中的表现。该评价纳入了 2013 年 1 月至 2020 年 12 月期间发表的所有研究。我们的结论是，CardioCel 是一种具有高强度、柔韧性的组织替代品，具有良好的操作特性，且血栓、动脉瘤形成、感染或结构退化的发生率低。它可用于各种年龄段的先天性心脏病的心脏内和心脏外修复，在中期随访中具有良好的耐久性。然而，在某些位置使用 CardioCel 需要谨慎。CardioCel 长期性能的信息尚缺乏。
